2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Pathology, Bioinformatics, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, ALL, LGL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

3267 Development of a novel, second generation dual IRAK1/IRAK4 proteolysis targeting chimera (DFCI-001-149) that is highly active in MYD88 mutated lymphoma cells including those with clinically relevant BTK mutations.

John Hatcher, PhD, Shirong Liu, PhD2, Amanda Kofides, MSc3, Jinhua Wang, PhD4, Xia Liu, MD5, Nickolas Tsakmaklis6, Maria Luisa Guerrera, MD7, Christopher Patterson, MBA, MPH8, Zachary R Hunter, PhD9, Shayna Sarosiek, MD10, Jorge J Castillo, MD11, Sara Buhrlage, PhD12, Steven Treon, MD, PhD13
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Harvard Medical School, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Harvard Medical School, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Background: Activating MYD88 mutations are prevalent in many B-cell malignancies including Waldenstrom’s Macroglobulinemia (95-97%), Primary CNS Lymphoma (70-80%), ABC Subtype of Diffuse Large B-cell Lymphoma (40%), Marginal Zone Lymphoma (10%) and Chronic Lymphocytic Leukemia (CLL) and promote malignant-cell survival through divergent HCK/BTK and IRAK1/4 signaling pathways. We previously developed JH-XIII-05-01, a first-generation dual IRAK1/4 PROTAC that combines degradation with kinase inhibition and shows synergistic activity with BTK-directed agents (Hatcher et al, Blood 2024; 144(S1):4359). However, JH-XIII-05-01 demonstrated low steady-state volume of distribution (Vss, 0.81 L/kg) and limited tumor-tissue distribution, prompting an extensive medicinal chemistry campaign to improve drug properties, including pharmacokinetic (PK) and pharmacodynamic (PD) activity.

Methods: JH-XIII-05-01 served as the benchmark for optimization of cereblon-recruiting dual IRAK1/4 degraders. Compounds were evaluated by immunoblotting, kinome profiling, matched global proteomics, and cell viability and apoptosis assays in MYD88 mutated lymphoma models, primary WM samples with paired CD19-negative cells, and TMD8 ABC DLBCL cells expressing wild-type (WT) BTK or clinically relevant BTK resistance mutations. Combination studies included covalent and non-covalent BTK inhibitors and BTK-directed degraders. In vitro ADME and mouse pharmacokinetic properties were also assessed.

Results: DFCI-001-149 demonstrated potent dual IRAK1/IRAK4 degradation and a kinome selectivity profile comparable to JH-XIII-05-01. DFCI-001-149 also showed synergistic activity with BTK-targeting agents, including zanubrutinib, pirtobrutinib, and BTK-directed degraders, supporting the feasibility of combining IRAK1/4 and BTK degradation. In TMD8 BTK WT cells, DFCI-001-149 was 2.3-fold more potent than JH-XIII-05-01 (EC50, 3.9 versus 9.2 nM) and retained low-nanomolar antiproliferative activity across clinically relevant BTK resistance models tested, including T474I, M437R, V416L, A428D, C481S, and L528W, while maintaining strong pro-apoptotic activity in the evaluated mutant models. In TMD8 BTK A428D cells, JH-XIII-05-01 and DFCI-001-149 induced 66.5% and 75.2% apoptosis, respectively, at 0.5 µM after overnight treatment, compared with 18.4% for vehicle and 19.6% for the cereblon-inactive control. In TMD8 WT cells, DFCI-001-149 induced 58.6% apoptosis versus 19.2%, 19.9%, and 18.6% for the IRAK1- or IRAK4-directed degraders JNJ-1013, KT-474, and KTX-582, respectively, increasing to 71.8% when combined with zanubrutinib. In six primary MYD88 mutated WM bone marrow samples treated overnight at 0.5 µM, DFCI-001-149 induced apoptosis in 40.5–84.1% of malignant CD19-positive cells, compared with 28.3–43.8% for JH-XIII-05-01 (p=0.012) and 16.7–28.9% for vehicle control (p=0.004) treated cells, while sparing paired bone marrow CD19-negative non-malignant cells. Matched proteomics showed preservation of a broader degradation signature, including PAK4, GAK, IKZF1/3, and CSNK1 family proteins. DFCI-001-149 also reduced MYC and increased TP53, CDKN1A, and MDM2, consistent with a p53-associated stress response that may contribute to its enhanced antiproliferative and apoptotic activity. Relative to JH-XIII-05-01, DFCI-001-149 showed threefold higher aqueous solubility and 5- to 12-fold longer half-lives in human and mouse microsomes and hepatocytes. These improvements translated in vivo to an increase in Vss from 0.81 to 2.31 L/kg, 50% lower IV clearance, and extension of the subcutaneous half-life from 2.0–2.7 to 6.1–6.3 hours. Tumor pharmacodynamic studies assessing tissue exposure and IRAK1/IRAK4 degradation are ongoing.

Conclusions: DFCI-001-149 is a novel, second-generation IRAK1/IRAK4 PROTAC with enhanced potency, pro-apoptotic activity, and synergistic tumor-cell killing with BTK inhibitors, including BTK-directed PROTACs, thereby supporting the feasibility of combined PROTAC therapy for WM. The pronounced activity of DFCI-001-149 in TMD8 cells expressing clinically relevant BTK mutations supports its further investigation as a strategy to overcome resistance to BTK-directed therapy. DFCI-001-149 also showed improved metabolic stability, systemic persistence, and distribution, consistent with improved pharmacokinetic properties.

John Hatcher, PhD: No relevant conflicts of interest to declare.